Sandra Karanović

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

Bojan Jelaković, Sandra Karanović, Ivana Vuković Lela et al. · Kidney International · 2011 · 209 citations · Full text

Nucleic Acid Chemistry, Biochemistry, Environmental Exposure +7

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid

Bojan Jelaković, Xavier Castells, Karla Tomić et al. · International Journal of Cancer · 2014 · 44 citations · Full text

Aristolochic Acid, Genetics, Renal Pathology +18

Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid

Xavier Castells, Sandra Karanović, Maude Ardin et al. · Cancer Epidemiology Biomarkers & Prevention · 2015 · 24 citations · Full text